Several centers established CD3+/CD19+ depletion as a feasible approach for patients lacking a suitable donor, with excellent primary engraftment and reduced rates of GVHD correlating with the remaining CD3+ cell/kg content of the graft. This evidence concerns the gene CD19 and graft versus host disease.